Maja Galić - Concepedia

Author

Maja Galić

Teva Pharmaceuticals (United States)

Also Known As

Galic, Marija, M Galić, M. Galic, Maja Galic, Maja Galić

Publications

953

Citations

H-Index

Concepts

All Affiliations

Teva Pharmaceuticals (United States)Teva Pharmaceuticals (Netherlands)The University of Melbourne Albert Einstein College of Medicine Teva Pharmaceuticals (Israel)

About

Maja Galić is an author at Teva Pharmaceuticals (United States) specializing in medicine, epidemiology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	622
2	Public Health	2	2	38
3	Engineering	1	1	83
4	Health Sciences	1	1	418
5	Allergy	1	1	83

Maja Galić

Publications

913

Citations

H-Index

Page 1

	Year	Citations
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial Michel D. Ferrari, Hans‐Christoph Diener, Xiaoping Ning, The Lancet Cluster HeadacheDocumented FailureClinical TrialsMigraine PreventionFremanezumab Versus Placebo	2019	418
Secretory Antibodies Do Not Affect the Composition of the Bacterial Microbiota in the Terminal Ileum of 10-Week-Old Mice Leanne Sait, Maja Galić, Richard A. Strugnell, Applied and Environmental Microbiology	2003	101
PCR-generated artefact from 16S rRNA gene-specific primers Catherine A. Osborne, Maja Galić, Parveen Sangwan, FEMS Microbiology Letters Different PrimersEngineeringGeneticsRna BiologyMolecular Biology	2005	83
Secretory antibodies reduce systemic antibody responses against the gastrointestinal commensal flora Leanne Sait, Maja Galić, Jason D. Price, International Immunology Systemic Antibody ResponsesDysbiosisAllergyAutoimmune DiseaseMucosal Immunology	2007	83
Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study Richard B. Lipton, Joshua M. Cohen, Maja Galić, Headache The Journal of Head and Face Pain	2021	52
Chronic <i>Helicobacter pylori</i> Infection Does Not Significantly Alter the Microbiota of the Murine Stomach Mai Ping Tan, Maria Kaparakis‐Liaskos, Maja Galić, Applied and Environmental Microbiology	2006	50
Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study Messoud Ashina, Joshua M. Cohen, Maja Galić, The Journal of Headache and Pain	2021	40
Impact of rotavirus vaccination in Australian children below 5 years of age Annmarie Pendleton, Maja Galić, Christopher Clarke, Human Vaccines & Immunotherapeutics VaccinationPreventive MedicineVaccine DevelopmentRotavirus VaccinationPediatric Epidemiology	2013	25
Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study Richard B. Lipton, Joshua M. Cohen, Kristen Bibeau, Headache The Journal of Head and Face Pain	2020	23
Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study Antoinette MaassenVanDenBrink, Gisela M. Terwindt, Joshua M. Cohen, The Journal of Headache and Pain	2021	14

Page 1